0HFR.LSE Anavex Life Sciences Corp.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -3.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is 0HFR.LSE undervalued?
Graham numberThe Graham number of Anavex Life Sciences Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Anavex Life Sciences Corp. fundamental analysis
No fundamental analysis for Anavex Life Sciences Corp. yet.
Anavex Life Sciences Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's dis…
Full company profileAnavex Life Sciences Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Anavex Life Sciences Corp. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | -685K | - | - | - | - | - | - | - |
| Gross Profit | -1.25K | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -15.6M | -15.7M | -19.3M | -29.1M | -31.1M | -42.0M | -51.0M | -55.8M | -52.9M | -51.4M | -8.71M |
| EBITDA | -15.0M | -15.4M | -1.48M | -28.4M | -3.92M | -4.73M | -50.9M | -49.3M | 5.29M | -47.0M | -7.26M |
| Net Income | -14.7M | -13.5M | -17.3M | -26.3M | -26.3M | -37.9M | -48.0M | -47.5M | -43.0M | -46.4M | -4.26M |
| EPS | -0.42 | -0.33 | -0.39 | -0.54 | -0.45 | -0.54 | -0.62 | -0.60 | -0.52 | -0.54 | -0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 9.50M | 27.8M | 26.2M | 25.3M | 34.5M | 162M | 153M | 154M | 136M | 104M | 120M |
| Total Liabilities | 3.19M | 3.58M | 3.88M | 5.04M | 7.31M | 10.8M | 10.2M | 12.5M | 15.3M | 8.95M | 7.69M |
| Shareholders' Equity | 6.31M | 24.3M | 22.3M | 20.3M | 27.2M | 151M | 142M | 142M | 120M | 94.9M | 112M |
| Cash & Short-term Investments | 9.19M | 27.4M | 22.9M | 22.2M | 29.2M | 152M | 149M | 151M | 132M | 103M | 118M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -9.24M | -9.02M | -12.7M | -18.6M | -21.3M | -30.4M | -24.2M | -27.8M | -30.8K | -39.0M | -23.2M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 4.00 | 4.00 | 4.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -9.24M | -9.02M | -12.7M | -18.6M | -21.3M | -30.4M | -24.2M | -27.8K | -30.8K | -39.0M | -23.2M |
| Ratios | |||||||||||
| ROE | -233.6% | -55.5% | -77.3% | -129.6% | -96.5% | -25.1% | -33.7% | -33.5% | -35.8% | -48.9% | -3.8% |
| ROA | -155.1% | -48.4% | -65.8% | -103.8% | -76.1% | -23.5% | -31.4% | -30.8% | -31.7% | -44.7% | -3.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Anavex Life Sciences Corp. dividends
Anavex Life Sciences Corp. has not paid dividends in the last 9 fiscal years.
Who owns Anavex Life Sciences Corp.
- Insiders 1.71%
- Institutions 40.17%
- Public & others 58.13%
- Free float 89.8M
Anavex Life Sciences Corp. company profile
- Company name
- Anavex Life Sciences Corp.
- Ticker
- 0HFR.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 34
- Fiscal year end
- September
- Address
- 630 5th Avenue, New York, NY, United States, 10111
- Phone
- 844 689 3939
- Website
- anavex.com
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, as well as exhibits anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71 that targets SIGMAR1 and M1 muscarinic receptors, which is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, such as cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Anavex Life Sciences Corp. management
2- Ms. Sandra Boenisch CPA, CGAPrincipal Financial Officer & Treasurer · born 1981
- Dr. Terrie Kellmeyer Ph.D.Interim Chief Executive Officer